Non-steroidal anti-inflammatory drugs: an overview
Non-steroidal anti-inflammatory drugs (NSAIDs) including both traditional non-selective NSAIDs and the selective cyclooxygenase (COX)-2 inhibitors, are widely used for their anti-inflammatory and analgesic effects. NSAIDs are a necessary choice in pain management because of the integrated role of the COX path way in the generation of inflammation and in the biochemical recognition of pain. NSAIDs are the competitive inhibitors of cyclooxygenase (COX), the enzyme which mediates the bioconversion of arachidonic acid to inflammatory prostaglandins (PGs). Their use is associated with the side effects such as gastrointestinal and renal toxicity. They are the most commonly employed first line drugs for all these conditions and many others-like musculoskeletal trauma, minor aches and pains, and dysmenorrhoea. The therapeutic anti-inflammatory action of NSAIDs is produced by the inhibition of COX-2, while the undesired side effects arise from inhibition of COX-1 activity. Thus, it was though those more selective COX-2 inhibitors would have reduced side effects. Based upon a number of selective COX-2 inhibitors (Rofecoxib, Celecoxib etc.) were developed as safer NSAIDs with improved gastric safety profile. Several newer applications like prophylaxis of stroke with aspirin are now common place. Use of these drugs for the prophylaxis of conditions like Alzheimer’s disease and colorectal cancer is being evaluated. Unfortunately, they have several toxicities ranging from minor heartburn to severe gastrointestinal haemorrhage and perforation. Therefore, newer NSAIDs have been introduced in recent years to circumvent this problem. In preliminary studies, these have shown better safety, efficacy, and tolerability but the full spectrum of adverse reactions of these drugs is yet to be fully known. This review can be used for further research as well as clinical purpose.
Keywords: Non-steroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase inhibitors, prostaglandins, aspirin.
2. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin like drugs. Nature 1971; 231.
3. Hata AW, Breyer RM. Pharmacology and signaling of prostaglandin receptors; multiple role in inflammation and immune modulation. Pharmaco Ther 2004; 103:147-66.
4. Smith WL, Marnett LJ. Prostaglandins endoperoxide synthase: structure and catalysis. Biochim biophys Acta 1991; 1083:1-17.
5. Grisold DE, Adams TC. Constitutive cyclooxygenase (cox-1) and inducible cyclooxygenase (Cox-2). Rationate for selective inhibition and progress to date Med Rev 1996; 16:181-206.
6. Garavito RM, Malkoswki MG, Dewitt DL. The structure of prostaglandins endoperoxide H synthase 1 and 2. Prostaglandins and others lipid mediators.
7. Vane JR, Balchle VS, Botting RM. Cycloxgenase 1 and 2. Annu Rev pharmacol Toxicol 1998; 38:97-120.
8. Dubois RN, Abramson SB, Croffod Gupta RA, Simon LS, Van de pulte lipsky PE. Cyclo oxyegenase in biology and disease. FASEBT 1998; 12:1063-73.
9. Wang D, Dubois RN. Prostaglandins and cancer. Gut 2006; 55:115-22.
10. NASH GF, Tumer LF, Scully MF Kakkar AK. Lancet on Platlets and cancer 2002; 3:425-30.
11. Towhead TE, Maxwell, Judd MG, Catton M, Hochberg MC, Well G. Acetaminophen for Osteoarthritis Cochrane database system Rev 2006; 1:CD004257.
12. Goodman and Gilman. The pharmacological basic of therapeutics anti-inflammatory anti-pyretic and analgesic agents pharmacotherapy of gout. 12th edition. New gone pergamon press, 2011.
13. De Armond B. Francisco CA, Lin JS et al. Safety profile of over the counter naproxen sodium. LIN THER 1995; 17:587-601.
14. Gutthann SP, García Rodríguez LA, Raiford DS. Individual non-steroidal anti-inflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997; 8(1):18–24.
15. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000; 321(7270):1183–7.
16. Weil J, Colin-Jones D, Langman M. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310(6983):827-30.
17. Moore N, Vanganse E, Leparc JM. The PAIN study: Paracetamol, Aspirin and Ibuprofen New tolerability study: a large-scale, randomised clinical trial comparing the tolerability of aspirin, ibuprofen and paracetamol for short-term analgesia. Clin Drug Investig 1999; 18(2):89–98.
18. Moore N, Charlesworth A, Van Ganse E. Risk factors for adverse events in analgesic drug users: results from the PAIN study. Pharmacoepidemiol Drug Saf.2003; 12(7):601–10.
19. Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005; 331(7528):1310–16.
20. Moore N, Salvo F, Duong M, Blin P, Pariente A. Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTC. Expert Opin Drug Saf 2014; 13(2):167–79.
21. Advil (ibuprofen) [package insert] Madison, NJ: Pfizer Consumer Healthcare; 2012.
22. Summary Minutes of the Joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee Meeting February 10–11, 2014. Silver Spring, MD: Food and Drug Administration; Center for Drug Evaluation and Research; 2014.
23. Weir MR. Renal effects of nonselective NSAIDs and coxibs. Cleve Clin J Med 2002; 69(Suppl 1):SI53–8.
24. Farquhar WB, Morgan AL, Zambraski EJ, Kenney WL. Effects of acetaminophen and ibuprofen on renal function in the stressed kidney. J Appl Physiol 1999; 86(2):598–604.
25. Paterson CA, Jacobs D, Rasmussen S, Youngberg SP, McGuinness N. Randomized, open-label, 5-way crossover study to evaluate the pharmacokinetic/pharmacodynamic interaction between furosemide and the non-steroidal anti-inflammatory drugs diclofenac and ibuprofen in healthy volunteers. Int J Clin Pharmacol Ther 2011; 49(8):477–90.
26. Weir MR. Renal effects of nonselective NSAIDs and coxibs. Cleve Clin J Med 2002; 69(Suppl 1):SI69–SI76.
27. Farquhar WB, Morgan AL, Zambraski EJ, Kenney WL. Effects of acetaminophen and ibuprofen on renal function in the stressed kidney. J Appl Physiol 1999; 86(2):711-7.
28. Greenblatt DJ, Von Moltke LL. Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol 2005; 45(2):127–32.
29. Thijssen HH, Soute BA, Vervoort LM, Claessens JG. Paracetamol (acetaminophen) warfarin interaction: NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle. Thromb Haemost 2004; 92(4):797–802.
30. Mahé I, Caulin C, Bergmann JF. Does paracetamol potentiate the effects of oral anticoagulants: a literature review. Drug Saf 2004; 27(5):325–33.
31. Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345(25):1809–17.
32. De Abajo FJ, Rodríguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999; 319(7217):1106–9.
33. De Jong JC, van den Berg PB, Tobi H, de Jong-van den Berg LT. Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. Br J Clin Pharmacol 2003; 55(6):591–5.
34. Schafer AI. Effects of non steroidal anti inflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol 1995; 35(3):209–19.
35. Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 2010; 71(12):1565–75.
36. Methotrexate sodium [package insert] Lake Zurich, IL: Fresenlus Kabi USA, LLC; 2013.
37. Tracy TS, Krohn K, Jones DR, Bradley JD, Hall SD, Brater DC. The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharmacol 1992; 42(2):121–5.
38. Haas DA. Adverse drug interactions in dental practice: interactions associated with analgesics, Part III in a series. J Am Dent Assoc 1999; 130(3):397–407.
39. Egan LJ. Drug interactions in gastroenterology: mechanisms, consequences, and how to avoid. Clin Gastroenterol Hepatol 2004; 2(9):725–30.
40. Murray MD, Black PK, Kuzmik DD et al. Acute and chronic effects of non steroidal anti inflammatory drugs on glomerular filtration rate in elderly patients. Am J Med Sci 1995; 310(5):188–97.
41. Li DK, Liu L, Odouli R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ 2003; 327(7411):368.
42. Majed BH, Khalil RA. Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn. Pharmacol Rev 2012; 64(3):540–82.
43. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of non-steroidal anti-inflammatory drugs. Ann Intern Med 1991; 114(9):735–40.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).